May #112 : A Peek in the Pipeline - by Tim Murphy

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

A Model Activist

Hep Cat

The Brave Lady of Haiti

Mighty Real

Big, Bad Media Bugout

Earthwatch

PEP on the Down Low

Quick Studies

Legal Eye

On the March!

Notes on Camp

Kentucky Fried Bigots?

POZ Picks

Hollywood to HIVers: Drop Dead

Ouch!

Veggie Table

Don't Run

A Peek in the Pipeline

Ducking Resistance

Quick Study

Pharm Team

Warning!

Haartbeats

Editor's Letter

Mailbox

Teen Jeopardy

Heavy Lifting



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

May 2005

A Peek in the Pipeline

by Tim Murphy

Super science (beyond superbugs) from the Conference on Retroviruses and Opportunistic Infections (CROI)

When researcher David Ho, MD, unleashed a media frenzy in February by announcing that a gay New York City man had contracted a multi-drug resistant, fast-progressing HIV strain (see “Big, Bad Media Bugout"), few doubted that he’d grab headlines two weeks later in Boston at CROI, the year’s top AIDS confab. The hoopla unfortunately overshadowed “the best [CROI] in years in terms of therapy progress,” says Project Inform’s Marty Delaney. Check these future features:

PROTEASE PROMISE  In Phase III trials, long-anticipated protease inhibitor (PI) tipranavir—the FDA will likely approve it this summer—performed better in protease-resistant HIVers than PI rivals like Kaletra. Tibotec’s PI contender TMC-114 may prove even more promising. In a large, six-month Phase II study of multidrug-resistant HIVers, TMC-114 combos smashed viral load on average by nearly two logs (say, from 60,000 to 600)—even to undetectable at the highest dose.

NON-NUKE NOTES  Over a year, adding Pfizer’s non-nuke capravirine to a PI-plus-two-nukes combo didn’t suppress non-nuke-resistant HIVers’ viral loads better than the combo without capravirine. But Tibotec scored again with non-nuke TMC-278, plunging viral loads in seven days. Larger TMC-278 trials start this spring.

NEW CLASSES  Drugs that stop HIV in novel ways are a-brewin’. For nine days, a single dose of Panacos’ maturation inhibitor PA-457—which blocks the same HIV step as PIs, but differently—dropped viral loads significantly. And in a tiny trial, Merck’s integrase inhibitor L-870810—which keeps HIV from stuffing its own DNA into human DNA—cut HIVers’ viral loads over 10 days of twice-daily dosing. Too bad toxicity in dog studies has shelved it, though Merck plans to proceed with a similar compound. Woof!



[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    chrisf
    san jose
    California


    Reginaldb06
    Dallas
    Texas


    pevans
    San Francisco
    California


    blaze11212
    brooklyn
    New York
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Do you work with your doc to design your own treatment regimen?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.